Experiment 69644
Worktypes
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Valeriana officinalis (VALERIANACEAE) |
| Citation | DONOVAN,JL: DEVANE,CL: CHAVIN,KD: WANG,JS: GIBSON,BB: GEFROH,HA: MARKOWITZ,JS:. (2004). MULTIPLE NIGHT-TIME DOSES OF VALERIAN (VALERIANA OFFICINALIS) HAD MINIMAL EFFECTS ON CYP3A4 ACTIVITY AND NO EFFECT ON CYP2D6 ACTIVITY IN HEALTHY VOLUNTEERS.. 32(12) |
| Amount utilized | |
| Compound isolated | |
| Disease | VALERIAN EXPOSURE (ALL P VALUES > OR=0.05; TIME TO REACH MAXIMUM CONCENTRATION IN PLASMA, 3.0+/-3.2 VERSUS 3.1+/-2.1H; AREA UNDER THE PLASMA CONCENTRATION VERSUS TIME CURVE, HALF-LIFE OF ELIMINATION. THE RESULTS INDICATE THAT ALTHOUGH A DEXTROMETHORPHAN TO DEXTORPHAN METABOLIC RATIOS (DMRS) AND ALPRAZOLAM PHARMACOKINETICS WERE DETERMINED AT BASELINE AND AFTER VALERIAN TREATMENT. THERE WERE NO SIGNIFICANT DIFFERENCES IN OTHER PHARMACOKINETIC PARAMETERS AT BASELINE AND AFTER ACTIVITY) WERE ADMINISTERED ORALLY TO HEALTHY VOLUNTEERS(N=12) AT BASELINE AND AGAIN AFTER EXPOSURE TO TWO 500 MG VALERIAN TABLETS (1000 MG) NIGHTLY FOR 14 DAYS. THE VALERIAN SUPPLIMENT CONTAINED A TOTAL VALERIC ACID CONTENT OF 5.51 MG/TABLET. THE OBJECTIVE OF THIS STUDY WAS TO ASSESS TH INFLUENCE OF VALERIAN EXTRACT ON THE ACTIVITY OF THE DRUG METABOLIZING ENZYMES CYTOCHROME P450 2D6 (CYP2D6) AND 3A4. PROBE DRUGS DEXTROMETHORPHAN (30 MG; CYP2D6 ACTIVITY) AND ALPRAZOAM (2 MG;CYP3A4 MODEST INCREASE WAS OBSERVED IN HTE ALPRAZOLAM CMAX, TYPICAL DOSES OF VALERIAN ARE LIKELY TO PRODUCE CLINICALLY SIGNIFICANT EFFECTS ON THE DISPOSITION OF MEDICATIONS DEPENDENT ON THE CYP2D6 OR CYP3A4 PATHWAYS OF METABOLISM. |
| Dose amount | 1.0 GM |
| Number | 1 |
| Qualitative result | INACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |
| Extract | HYDRO-ALCOHOLIC EXT |
| Gender | GIVEN TO BOTH SEXES |